Analyst Price Target Update on Cerus Corporation (NASDAQ:CERS)

Cerus Corporation (NASDAQ:CERS): According to 4 Analysts, The short term target price has been estimated at $ 9.25.The target price could deviate by a maximum of $0.96 from the forecast price. In the near term, the target price could hit a high of $10 and a low of $ 8.

Many analysts have stated their opinion on the company shares. BTIG Research maintains its rating on Cerus Corporation (NASDAQ:CERS). The global brokerage major raises the current price target from $8 per share to $10 per share. Analysts at the BTIG Research have a current rating of Buy on the shares. The rating by the firm was issued on April 22, 2016. For this week, the average consensus of the company shares are rated as a Strong Buy.

On the companys insider trading activities,The officer (Chief Legal Officer) of Cerus Corp, Menard Chrystal sold 8,541 shares at $5.62 on March 11, 2016. The Insider selling transaction had a total value worth of $48,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Cerus Corporation (NASDAQ:CERS) witnessed a volatile trading activity on Monday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $6.03 and reached the intraday high at $6.18. The bulls started the profit booking and pushed the shares to intraday low of $5.96. The trading session was marked by a volume range of 1,284,190 shares exchanging hands. The 52-week high of the shares is $6.89 and the 52-week low is $4.27. The market cap of the company stands at $619 million and there are 101,710,815 shares in public circulation.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.